PMV Pharmaceuticals
First-in-class p53 Reactivators

PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

 


University
Rutgers University
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website